HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy

European Meeting on HIV & Hepatitis 2020

Role of analytical treatment interruption on HIV peripheral reservoir diversification

European Meeting on HIV & Hepatitis 2020

Similar levels of HIV-DNA and residual viremia are found in virologically suppressed individuals who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to EVG/COBI/FTC enrolled in the Be-OnE Study

European Meeting on HIV & Hepatitis 2020

Comprehensive assessment of SARS-CoV-2 key genetic elements single or in clusters underlying geographically-dependent genetic evolutionary adaptation and their impact on drugs binding affinity and immune escape

European Meeting on HIV & Hepatitis 2020

Case report: poor adherence to dolutegravir is associated with selection of resistance mutations T66I, G118R, E138A and L74I

European Meeting on HIV & Hepatitis 2020

Integrase Resistance development after long-term suppressive treatment with Abacavir, Lamivudine and Dolutegravir

European Meeting on HIV & Hepatitis 2020

Difficulty in reaching virological suppression in a long-term treated HIV-1 patient: rather the role of the reservoir than drug resistance?

European Meeting on HIV & Hepatitis 2020

Assessment of quality of life among patients with hepatitis C in Georgia

European Meeting on HIV & Hepatitis 2020

HIV Seronegativity After Rapid ART: A Case Demonstrating Future Challenges in HIV Confirmation Testing in the Era of iART

European Meeting on HIV & Hepatitis 2020

Multicentric Castleman Disease HHV-8 related in a HIV patient

European Meeting on HIV & Hepatitis 2020

Variability in HIV Proviral DNA Genotyping Results from a Single Blood Draw

European Meeting on HIV & Hepatitis 2020

Virological efficacy and resistance evaluation in people living with HIV starting an STR regimen

European Meeting on HIV & Hepatitis 2020

Resistant minority variants observed in failing patients at week 48 in ANRS 170 QUATUOR trial (a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load)

European Meeting on HIV & Hepatitis 2020

Molecular characterization in HCV late relapser patients treated with direct-acting antiviral (DAA) drugs

European Meeting on HIV & Hepatitis 2020

Clinical and virological characteristics and retreatment of patients with chronic hepatitis C virus infection and failure to sofosbuvir, velapatasvir, and voxilaprevir in real-world

European Meeting on HIV & Hepatitis 2020

Pharmaco-virological algorithm to target risk of resistance among a population of HIV-infected female sex workers in Togo

European Meeting on HIV & Hepatitis 2020

Characterization of the NS5A gene of HCV genotype 4 isolates from HIV-1 co-infected patients in a third-level hospital in Mexico

European Meeting on HIV & Hepatitis 2020

Impact of Sexually Transmitted Infections on seminal HIV levels among undetectable patients

European Meeting on HIV & Hepatitis 2020

Bone mineral density in patients with HIV infection and chronic hepatitis C

European Meeting on HIV & Hepatitis 2020

The burden of serious non-AIDS-defining events among admitted cART-naive HIV/AIDS patients in China: An observational cohort study

European Meeting on HIV & Hepatitis 2020

The prevalence of hepatitis B virus seromarkers in patients with HIV/HCV coinfection. An Egyptian cross-sectional study.

European Meeting on HIV & Hepatitis 2020

Seroprevalence and co-infections HIV, HBV and HCV among clinic attenders at Laquintinie Hospital in Douala, Cameroon

European Meeting on HIV & Hepatitis 2020

HIV-DNA from rectal GALT is a valid marker to explore the viral latency

European Meeting on HIV & Hepatitis 2020

The efficacy of first-line therapy based on RPV in HIV-infected patients with pre-existing E138A mutation in reverse transcriptase

European Meeting on HIV & Hepatitis 2020